Chongqing Zhifei Biological Products Management
Management criteria checks 4/4
Chongqing Zhifei Biological Products' CEO is Rensheng Jiang, appointed in Aug 2009, has a tenure of 15.33 years. directly owns 48.44% of the company’s shares, worth CN¥32.65B. The average tenure of the management team and the board of directors is 6.3 years and 6.5 years respectively.
Key information
Rensheng Jiang
Chief executive officer
CN¥980.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 15.3yrs |
| CEO ownership | 48.4% |
| Management average tenure | 6.3yrs |
| Board average tenure | 6.5yrs |
Recent management updates
Recent updates
These 4 Measures Indicate That Chongqing Zhifei Biological Products (SZSE:300122) Is Using Debt Reasonably Well
Nov 26
Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
Sep 30Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Analysts Are More Bearish Than They Used To Be
Sep 03Calculating The Fair Value Of Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122)
Aug 23We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt
Jul 26Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E
May 21Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts
Apr 26Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?
Mar 26CEO
Rensheng Jiang (71 yo)
15.3yrs
Tenure
CN¥980,000
Compensation
Mr. Rensheng Jiang is Chairman of the Board & CEO of Chongqing Zhifei Biological Products Co., Ltd. from June 2002. He joined the Chongqing Zhifei Biological Products Co., Ltd.in August 2009. He is Direct...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 15.3yrs | CN¥980.00k | 48.44% CN¥ 32.7b | |
| Vice Chairman & VP | 15.3yrs | CN¥1.18m | 5.41% CN¥ 3.6b | |
| VP, CFO & Director | no data | CN¥1.24m | no data | |
| Chief Engineer | 5.7yrs | CN¥1.18m | no data | |
| VP, Secretary of Board & Director | no data | CN¥1.18m | no data | |
| Vice President | no data | CN¥1.24m | no data | |
| Assistant to the President | 6.3yrs | CN¥920.00k | no data |
6.3yrs
Average Tenure
44yo
Average Age
Experienced Management: 300122's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 15.3yrs | CN¥980.00k | 48.44% CN¥ 32.7b | |
| Vice Chairman & VP | 15.3yrs | CN¥1.18m | 5.41% CN¥ 3.6b | |
| VP, CFO & Director | 6.7yrs | CN¥1.24m | no data | |
| VP, Secretary of Board & Director | 6.7yrs | CN¥1.18m | no data | |
| Independent Director | less than a year | CN¥67.10k | no data | |
| Independent Director | 3.3yrs | CN¥195.00k | no data | |
| Independent Director | 3.5yrs | CN¥195.00k | no data | |
| Non-Independent Director | 7.7yrs | CN¥1.28m | no data | |
| Non-Independent Director | 6.3yrs | CN¥1.28m | no data | |
| Employee Representative Supervisor | no data | no data | 0.000080% CN¥ 53.9k | |
| Independent Director | 3.3yrs | CN¥195.00k | no data |
6.5yrs
Average Tenure
55yo
Average Age
Experienced Board: 300122's board of directors are considered experienced (6.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:55 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chongqing Zhifei Biological Products Co., Ltd. is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Zhang | AJ Securities Co., Ltd |
| Bo Li | BofA Global Research |
| Yuanrui Liu | Changjiang Securities Co. LTD. |